nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—Crohn's disease—psoriatic arthritis	0.529	1	CtDrD
Mesalazine—IKBKB—Auranofin—psoriatic arthritis	0.325	0.881	CbGbCtD
Mesalazine—PTGS2—Triamcinolone—psoriatic arthritis	0.0185	0.0503	CbGbCtD
Mesalazine—PTGS2—Betamethasone—psoriatic arthritis	0.0159	0.0432	CbGbCtD
Mesalazine—PTGS2—Dexamethasone—psoriatic arthritis	0.00925	0.0251	CbGbCtD
Mesalazine—MPO—IL23-mediated signaling events—IL23R—psoriatic arthritis	0.00236	0.0547	CbGpPWpGaD
Mesalazine—MPO—IL23-mediated signaling events—IL23A—psoriatic arthritis	0.002	0.0465	CbGpPWpGaD
Mesalazine—IKBKB—IL17 signaling pathway—TRAF3IP2—psoriatic arthritis	0.00178	0.0414	CbGpPWpGaD
Mesalazine—IKBKB—Atypical NF-kappaB pathway—REL—psoriatic arthritis	0.00121	0.028	CbGpPWpGaD
Mesalazine—CHUK—NOD pathway—MEFV—psoriatic arthritis	0.00101	0.0235	CbGpPWpGaD
Mesalazine—MPO—IL23-mediated signaling events—IL17A—psoriatic arthritis	0.000938	0.0218	CbGpPWpGaD
Mesalazine—IKBKB—NOD pathway—MEFV—psoriatic arthritis	0.000918	0.0213	CbGpPWpGaD
Mesalazine—MPO—IL23-mediated signaling events—IL12B—psoriatic arthritis	0.000872	0.0203	CbGpPWpGaD
Mesalazine—CHUK—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—MEFV—psoriatic arthritis	0.000863	0.0201	CbGpPWpGaD
Mesalazine—IKBKB—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—MEFV—psoriatic arthritis	0.000783	0.0182	CbGpPWpGaD
Mesalazine—CHUK—Canonical NF-kappaB pathway—NOD2—psoriatic arthritis	0.000605	0.0141	CbGpPWpGaD
Mesalazine—IKBKB—Canonical NF-kappaB pathway—NOD2—psoriatic arthritis	0.000548	0.0127	CbGpPWpGaD
Mesalazine—CHUK—TAK1 activates NFkB by phosphorylation and activation of IKKs complex—NOD2—psoriatic arthritis	0.000548	0.0127	CbGpPWpGaD
Mesalazine—IKBKB—IL17 signaling pathway—IL17A—psoriatic arthritis	0.000537	0.0125	CbGpPWpGaD
Mesalazine—CHUK—Apoptosis—LTA—psoriatic arthritis	0.000521	0.0121	CbGpPWpGaD
Mesalazine—IKBKB—TAK1 activates NFkB by phosphorylation and activation of IKKs complex—NOD2—psoriatic arthritis	0.000497	0.0116	CbGpPWpGaD
Mesalazine—MPO—IL23-mediated signaling events—NOS2—psoriatic arthritis	0.000489	0.0114	CbGpPWpGaD
Mesalazine—CHUK—TNF receptor signaling pathway —TNFRSF1B—psoriatic arthritis	0.000485	0.0113	CbGpPWpGaD
Mesalazine—CHUK—NOD1/2 Signaling Pathway—NOD2—psoriatic arthritis	0.000476	0.0111	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—LTA—psoriatic arthritis	0.000473	0.011	CbGpPWpGaD
Mesalazine—CHUK—IL-1 signaling pathway—REL—psoriatic arthritis	0.000445	0.0103	CbGpPWpGaD
Mesalazine—IKBKB—TNF receptor signaling pathway —TNFRSF1B—psoriatic arthritis	0.00044	0.0102	CbGpPWpGaD
Mesalazine—IKBKB—NOD1/2 Signaling Pathway—NOD2—psoriatic arthritis	0.000432	0.01	CbGpPWpGaD
Mesalazine—MPO—Vitamin B12 Metabolism—CRP—psoriatic arthritis	0.000415	0.00963	CbGpPWpGaD
Mesalazine—IKBKB—IL-1 signaling pathway—REL—psoriatic arthritis	0.000403	0.00937	CbGpPWpGaD
Mesalazine—CHUK—Activation of NF-kappaB in B cells—REL—psoriatic arthritis	0.000389	0.00904	CbGpPWpGaD
Mesalazine—CHUK—Interleukin-1 signaling—NOD2—psoriatic arthritis	0.000389	0.00903	CbGpPWpGaD
Mesalazine—CHUK—NOD pathway—NOD2—psoriatic arthritis	0.000381	0.00885	CbGpPWpGaD
Mesalazine—PTGS1—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.000374	0.00868	CbGpPWpGaD
Mesalazine—IKBKB—Activation of NF-kappaB in B cells—REL—psoriatic arthritis	0.000353	0.0082	CbGpPWpGaD
Mesalazine—IKBKB—Interleukin-1 signaling—NOD2—psoriatic arthritis	0.000352	0.00818	CbGpPWpGaD
Mesalazine—CHUK—Leptin signaling pathway—REL—psoriatic arthritis	0.000347	0.00807	CbGpPWpGaD
Mesalazine—IKBKB—NOD pathway—NOD2—psoriatic arthritis	0.000345	0.00802	CbGpPWpGaD
Mesalazine—MPO—Folate Metabolism—CRP—psoriatic arthritis	0.000337	0.00784	CbGpPWpGaD
Mesalazine—CHUK—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NOD2—psoriatic arthritis	0.000325	0.00755	CbGpPWpGaD
Mesalazine—IKBKB—Leptin signaling pathway—REL—psoriatic arthritis	0.000315	0.00731	CbGpPWpGaD
Mesalazine—CHUK—TCR Signaling Pathway—REL—psoriatic arthritis	0.0003	0.00697	CbGpPWpGaD
Mesalazine—CHUK—Apoptosis—TNFRSF1B—psoriatic arthritis	0.000299	0.00696	CbGpPWpGaD
Mesalazine—PTGS2—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.000297	0.00689	CbGpPWpGaD
Mesalazine—CHUK—TNF alpha Signaling Pathway—REL—psoriatic arthritis	0.000295	0.00685	CbGpPWpGaD
Mesalazine—IKBKB—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NOD2—psoriatic arthritis	0.000295	0.00685	CbGpPWpGaD
Mesalazine—CHUK—B Cell Receptor Signaling Pathway—REL—psoriatic arthritis	0.000283	0.00657	CbGpPWpGaD
Mesalazine—CHUK—TNF alpha Signaling Pathway—TNFRSF1B—psoriatic arthritis	0.000278	0.00647	CbGpPWpGaD
Mesalazine—IKBKB—TCR Signaling Pathway—REL—psoriatic arthritis	0.000272	0.00632	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—TNFRSF1B—psoriatic arthritis	0.000272	0.00631	CbGpPWpGaD
Mesalazine—MPO—Selenium Micronutrient Network—CRP—psoriatic arthritis	0.000268	0.00623	CbGpPWpGaD
Mesalazine—IKBKB—TNF alpha Signaling Pathway—REL—psoriatic arthritis	0.000267	0.00621	CbGpPWpGaD
Mesalazine—PTGS2—Fluocinonide—Methylprednisolone—psoriatic arthritis	0.000266	0.159	CbGdCrCtD
Mesalazine—PTGS2—Fluocinonide—Betamethasone—psoriatic arthritis	0.000262	0.156	CbGdCrCtD
Mesalazine—PTGS2—Fluocinonide—Dexamethasone—psoriatic arthritis	0.000262	0.156	CbGdCrCtD
Mesalazine—CHUK—Downstream TCR signaling—HLA-DRB1—psoriatic arthritis	0.000259	0.00602	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Receptor Signaling Pathway—REL—psoriatic arthritis	0.000256	0.00595	CbGpPWpGaD
Mesalazine—PTGS2—Fluocinonide—Triamcinolone—psoriatic arthritis	0.000256	0.153	CbGdCrCtD
Mesalazine—IKBKB—Apoptosis Modulation and Signaling—TNFRSF1B—psoriatic arthritis	0.000255	0.00592	CbGpPWpGaD
Mesalazine—ALOX5—Selenium Micronutrient Network—CRP—psoriatic arthritis	0.000253	0.00588	CbGpPWpGaD
Mesalazine—CHUK—TCR Signaling Pathway—IL17A—psoriatic arthritis	0.000253	0.00587	CbGpPWpGaD
Mesalazine—IKBKB—TNF alpha Signaling Pathway—TNFRSF1B—psoriatic arthritis	0.000252	0.00587	CbGpPWpGaD
Mesalazine—MPO—IL23-mediated signaling events—TNF—psoriatic arthritis	0.000243	0.00564	CbGpPWpGaD
Mesalazine—IKBKB—Downstream TCR signaling—HLA-DRB1—psoriatic arthritis	0.000235	0.00546	CbGpPWpGaD
Mesalazine—CHUK—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—psoriatic arthritis	0.000235	0.00546	CbGpPWpGaD
Mesalazine—IKBKB—TCR Signaling Pathway—IL17A—psoriatic arthritis	0.000229	0.00532	CbGpPWpGaD
Mesalazine—PTGS2—skeletal joint—psoriatic arthritis	0.000216	0.213	CbGeAlD
Mesalazine—PPARG—Transcription factor regulation in adipogenesis—TNF—psoriatic arthritis	0.000215	0.00499	CbGpPWpGaD
Mesalazine—IKBKB—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—psoriatic arthritis	0.000213	0.00495	CbGpPWpGaD
Mesalazine—CHUK—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000213	0.00494	CbGpPWpGaD
Mesalazine—CHUK—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.000212	0.00494	CbGpPWpGaD
Mesalazine—CHUK—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.000211	0.00489	CbGpPWpGaD
Mesalazine—CHUK—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.000207	0.0048	CbGpPWpGaD
Mesalazine—CHUK—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.0002	0.00464	CbGpPWpGaD
Mesalazine—CHUK—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000196	0.00456	CbGpPWpGaD
Mesalazine—CHUK—Canonical NF-kappaB pathway—TNF—psoriatic arthritis	0.000195	0.00452	CbGpPWpGaD
Mesalazine—CHUK—EBV LMP1 signaling—TNF—psoriatic arthritis	0.000195	0.00452	CbGpPWpGaD
Mesalazine—CHUK—TCR signaling—HLA-DRB1—psoriatic arthritis	0.000194	0.0045	CbGpPWpGaD
Mesalazine—IKBKB—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000193	0.00448	CbGpPWpGaD
Mesalazine—IKBKB—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.000193	0.00448	CbGpPWpGaD
Mesalazine—IKBKB—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.000191	0.00444	CbGpPWpGaD
Mesalazine—CHUK—MyD88-independent cascade—NOD2—psoriatic arthritis	0.000188	0.00437	CbGpPWpGaD
Mesalazine—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriatic arthritis	0.000188	0.00437	CbGpPWpGaD
Mesalazine—MPO—Vitamin B12 Metabolism—TNF—psoriatic arthritis	0.000188	0.00436	CbGpPWpGaD
Mesalazine—IKBKB—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.000187	0.00436	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000183	0.00425	CbGpPWpGaD
Mesalazine—IKBKB—Type II diabetes mellitus—TNF—psoriatic arthritis	0.000183	0.00425	CbGpPWpGaD
Mesalazine—IKBKB—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.000181	0.0042	CbGpPWpGaD
Mesalazine—IKBKB—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000178	0.00413	CbGpPWpGaD
Mesalazine—CHUK—TCR signaling in naïve CD4+ T cells—HLA-DRB1—psoriatic arthritis	0.000177	0.00412	CbGpPWpGaD
Mesalazine—IKBKB—Canonical NF-kappaB pathway—TNF—psoriatic arthritis	0.000176	0.0041	CbGpPWpGaD
Mesalazine—IKBKB—EBV LMP1 signaling—TNF—psoriatic arthritis	0.000176	0.0041	CbGpPWpGaD
Mesalazine—IKBKB—TCR signaling—HLA-DRB1—psoriatic arthritis	0.000176	0.00408	CbGpPWpGaD
Mesalazine—CHUK—Signaling by Interleukins—NOD2—psoriatic arthritis	0.000176	0.00408	CbGpPWpGaD
Mesalazine—IKBKB—MyD88-independent cascade—NOD2—psoriatic arthritis	0.000171	0.00396	CbGpPWpGaD
Mesalazine—CHUK—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.000169	0.00393	CbGpPWpGaD
Mesalazine—PTGS1—Overview of nanoparticle effects—TNF—psoriatic arthritis	0.000169	0.00393	CbGpPWpGaD
Mesalazine—CHUK—AGE/RAGE pathway—NOS2—psoriatic arthritis	0.000169	0.00392	CbGpPWpGaD
Mesalazine—CHUK—Rac1/Pak1/p38/MMP-2 pathway—NOS2—psoriatic arthritis	0.000167	0.00387	CbGpPWpGaD
Mesalazine—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriatic arthritis	0.000166	0.00386	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000166	0.00385	CbGpPWpGaD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.000166	0.00385	CbGpPWpGaD
Mesalazine—PTGS2—synovial membrane of synovial joint—psoriatic arthritis	0.000164	0.162	CbGeAlD
Mesalazine—CHUK—B Cell Activation—REL—psoriatic arthritis	0.000162	0.00376	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—HLA-C—psoriatic arthritis	0.000161	0.00373	CbGpPWpGaD
Mesalazine—IKBKB—TCR signaling in naïve CD4+ T cells—HLA-DRB1—psoriatic arthritis	0.000161	0.00373	CbGpPWpGaD
Mesalazine—PTGS2—Fluticasone Propionate—Methylprednisolone—psoriatic arthritis	0.00016	0.0957	CbGdCrCtD
Mesalazine—CHUK—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.000159	0.0037	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by Interleukins—NOD2—psoriatic arthritis	0.000159	0.0037	CbGpPWpGaD
Mesalazine—PTGS2—Fluticasone Propionate—Betamethasone—psoriatic arthritis	0.000158	0.0942	CbGdCrCtD
Mesalazine—PTGS2—Fluticasone Propionate—Dexamethasone—psoriatic arthritis	0.000158	0.0942	CbGdCrCtD
Mesalazine—PTGS2—Fluticasone Propionate—Triamcinolone—psoriatic arthritis	0.000154	0.0921	CbGdCrCtD
Mesalazine—IKBKB—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.000153	0.00357	CbGpPWpGaD
Mesalazine—IKBKB—AGE/RAGE pathway—NOS2—psoriatic arthritis	0.000153	0.00355	CbGpPWpGaD
Mesalazine—MPO—Folate Metabolism—TNF—psoriatic arthritis	0.000153	0.00355	CbGpPWpGaD
Mesalazine—CHUK—skin of body—psoriatic arthritis	0.000151	0.149	CbGeAlD
Mesalazine—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—NOS2—psoriatic arthritis	0.000151	0.00351	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.00015	0.00349	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—REL—psoriatic arthritis	0.000147	0.00341	CbGpPWpGaD
Mesalazine—CHUK—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—psoriatic arthritis	0.000146	0.00339	CbGpPWpGaD
Mesalazine—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.000144	0.00335	CbGpPWpGaD
Mesalazine—CHUK—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.000142	0.00329	CbGpPWpGaD
Mesalazine—PTGS2—Overview of nanoparticle effects—TNF—psoriatic arthritis	0.000134	0.00312	CbGpPWpGaD
Mesalazine—IKBKB—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.000129	0.00299	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—MEFV—psoriatic arthritis	0.000122	0.00283	CbGpPWpGaD
Mesalazine—MPO—Selenium Micronutrient Network—TNF—psoriatic arthritis	0.000121	0.00282	CbGpPWpGaD
Mesalazine—CHUK—TWEAK Signaling Pathway—TNF—psoriatic arthritis	0.00012	0.00279	CbGpPWpGaD
Mesalazine—ALOX5—Selenium Micronutrient Network—TNF—psoriatic arthritis	0.000114	0.00266	CbGpPWpGaD
Mesalazine—CHUK—TNF receptor signaling pathway —TNF—psoriatic arthritis	0.000112	0.0026	CbGpPWpGaD
Mesalazine—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriatic arthritis	0.000111	0.00259	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000111	0.00259	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MEFV—psoriatic arthritis	0.000111	0.00257	CbGpPWpGaD
Mesalazine—PTGS1—Selenium Micronutrient Network—CRP—psoriatic arthritis	0.00011	0.00255	CbGpPWpGaD
Mesalazine—IKBKB—TWEAK Signaling Pathway—TNF—psoriatic arthritis	0.000109	0.00253	CbGpPWpGaD
Mesalazine—IKBKB—skin of body—psoriatic arthritis	0.000103	0.101	CbGeAlD
Mesalazine—IKBKB—TNF receptor signaling pathway —TNF—psoriatic arthritis	0.000101	0.00235	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000101	0.00235	CbGpPWpGaD
Mesalazine—CHUK—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	9.69e-05	0.00225	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—HLA-B—psoriatic arthritis	9.51e-05	0.00221	CbGpPWpGaD
Mesalazine—IKBKB—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	8.79e-05	0.00204	CbGpPWpGaD
Mesalazine—PTGS2—Selenium Micronutrient Network—CRP—psoriatic arthritis	8.71e-05	0.00202	CbGpPWpGaD
Mesalazine—PPARG—Signaling events mediated by HDAC Class I—TNF—psoriatic arthritis	8.51e-05	0.00198	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	8.19e-05	0.0019	CbGpPWpGaD
Mesalazine—PPARG—Transcriptional regulation of white adipocyte differentiation—TNF—psoriatic arthritis	7.89e-05	0.00183	CbGpPWpGaD
Mesalazine—IKBKB—tendon—psoriatic arthritis	7.82e-05	0.077	CbGeAlD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	7.43e-05	0.00173	CbGpPWpGaD
Mesalazine—PPARG—Circadian rythm related genes—NOS2—psoriatic arthritis	7.37e-05	0.00171	CbGpPWpGaD
Mesalazine—MPO—skin of body—psoriatic arthritis	7.21e-05	0.071	CbGeAlD
Mesalazine—CHUK—Immune System—MEFV—psoriatic arthritis	7.11e-05	0.00165	CbGpPWpGaD
Mesalazine—CHUK—Apoptosis—TNF—psoriatic arthritis	6.91e-05	0.0016	CbGpPWpGaD
Mesalazine—CHUK—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	6.91e-05	0.0016	CbGpPWpGaD
Mesalazine—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	6.62e-05	0.00154	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	6.59e-05	0.00153	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—REL—psoriatic arthritis	6.52e-05	0.00151	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MEFV—psoriatic arthritis	6.44e-05	0.0015	CbGpPWpGaD
Mesalazine—CHUK—TNF alpha Signaling Pathway—TNF—psoriatic arthritis	6.42e-05	0.00149	CbGpPWpGaD
Mesalazine—PPARG—skin of body—psoriatic arthritis	6.4e-05	0.063	CbGeAlD
Mesalazine—PTGS2—Spinal Cord Injury—NOS2—psoriatic arthritis	6.28e-05	0.00146	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—TNF—psoriatic arthritis	6.26e-05	0.00145	CbGpPWpGaD
Mesalazine—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	6.26e-05	0.00145	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—HLA-C—psoriatic arthritis	6.25e-05	0.00145	CbGpPWpGaD
Mesalazine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriatic arthritis	6.19e-05	0.00144	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HLA-C—psoriatic arthritis	6e-05	0.00139	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	5.97e-05	0.00139	CbGpPWpGaD
Mesalazine—CHUK—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	5.91e-05	0.00137	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—REL—psoriatic arthritis	5.91e-05	0.00137	CbGpPWpGaD
Mesalazine—IKBKB—TNF alpha Signaling Pathway—TNF—psoriatic arthritis	5.82e-05	0.00135	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HLA-C—psoriatic arthritis	5.66e-05	0.00132	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	5.58e-05	0.0013	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HLA-C—psoriatic arthritis	5.44e-05	0.00126	CbGpPWpGaD
Mesalazine—IKBKB—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	5.36e-05	0.00125	CbGpPWpGaD
Mesalazine—PPARG—Adipogenesis—TNF—psoriatic arthritis	5.19e-05	0.0012	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	5.06e-05	0.00117	CbGpPWpGaD
Mesalazine—PTGS1—Selenium Micronutrient Network—TNF—psoriatic arthritis	4.96e-05	0.00115	CbGpPWpGaD
Mesalazine—Infection—Methylprednisolone—psoriatic arthritis	4.88e-05	0.000857	CcSEcCtD
Mesalazine—PPARG—tendon—psoriatic arthritis	4.87e-05	0.0479	CbGeAlD
Mesalazine—Haematuria—Methotrexate—psoriatic arthritis	4.86e-05	0.000853	CcSEcCtD
Mesalazine—Shock—Triamcinolone—psoriatic arthritis	4.85e-05	0.00085	CcSEcCtD
Mesalazine—Insomnia—Prednisolone—psoriatic arthritis	4.85e-05	0.00085	CcSEcCtD
Mesalazine—Alopecia—Prednisone—psoriatic arthritis	4.84e-05	0.000849	CcSEcCtD
Mesalazine—Shock—Methylprednisolone—psoriatic arthritis	4.84e-05	0.000848	CcSEcCtD
Mesalazine—Hepatobiliary disease—Methotrexate—psoriatic arthritis	4.83e-05	0.000846	CcSEcCtD
Mesalazine—Nervous system disorder—Methylprednisolone—psoriatic arthritis	4.82e-05	0.000846	CcSEcCtD
Mesalazine—Loss of consciousness—Betamethasone—psoriatic arthritis	4.81e-05	0.000844	CcSEcCtD
Mesalazine—Loss of consciousness—Dexamethasone—psoriatic arthritis	4.81e-05	0.000844	CcSEcCtD
Mesalazine—Epistaxis—Methotrexate—psoriatic arthritis	4.81e-05	0.000844	CcSEcCtD
Mesalazine—Paraesthesia—Prednisolone—psoriatic arthritis	4.81e-05	0.000844	CcSEcCtD
Mesalazine—Tachycardia—Triamcinolone—psoriatic arthritis	4.81e-05	0.000843	CcSEcCtD
Mesalazine—Mental disorder—Prednisone—psoriatic arthritis	4.8e-05	0.000842	CcSEcCtD
Mesalazine—Tachycardia—Methylprednisolone—psoriatic arthritis	4.8e-05	0.000842	CcSEcCtD
Mesalazine—Skin disorder—Methylprednisolone—psoriatic arthritis	4.78e-05	0.000838	CcSEcCtD
Mesalazine—Erythema—Prednisone—psoriatic arthritis	4.77e-05	0.000837	CcSEcCtD
Mesalazine—Hyperhidrosis—Triamcinolone—psoriatic arthritis	4.76e-05	0.000835	CcSEcCtD
Mesalazine—Agranulocytosis—Methotrexate—psoriatic arthritis	4.76e-05	0.000835	CcSEcCtD
Mesalazine—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	4.75e-05	0.000834	CcSEcCtD
Mesalazine—Hypertension—Betamethasone—psoriatic arthritis	4.73e-05	0.000829	CcSEcCtD
Mesalazine—Hypertension—Dexamethasone—psoriatic arthritis	4.73e-05	0.000829	CcSEcCtD
Mesalazine—Myalgia—Dexamethasone—psoriatic arthritis	4.66e-05	0.000818	CcSEcCtD
Mesalazine—Myalgia—Betamethasone—psoriatic arthritis	4.66e-05	0.000818	CcSEcCtD
Mesalazine—Anxiety—Dexamethasone—psoriatic arthritis	4.65e-05	0.000815	CcSEcCtD
Mesalazine—Anxiety—Betamethasone—psoriatic arthritis	4.65e-05	0.000815	CcSEcCtD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	4.62e-05	0.00107	CbGpPWpGaD
Mesalazine—Discomfort—Dexamethasone—psoriatic arthritis	4.61e-05	0.000808	CcSEcCtD
Mesalazine—Discomfort—Betamethasone—psoriatic arthritis	4.61e-05	0.000808	CcSEcCtD
Mesalazine—Haemoglobin—Methotrexate—psoriatic arthritis	4.6e-05	0.000807	CcSEcCtD
Mesalazine—Hypotension—Methylprednisolone—psoriatic arthritis	4.59e-05	0.000806	CcSEcCtD
Mesalazine—CHUK—Innate Immune System—NOD2—psoriatic arthritis	4.59e-05	0.00107	CbGpPWpGaD
Mesalazine—Pain—Prednisolone—psoriatic arthritis	4.58e-05	0.000804	CcSEcCtD
Mesalazine—Hepatitis—Methotrexate—psoriatic arthritis	4.58e-05	0.000803	CcSEcCtD
Mesalazine—Haemorrhage—Methotrexate—psoriatic arthritis	4.58e-05	0.000803	CcSEcCtD
Mesalazine—Pharyngitis—Methotrexate—psoriatic arthritis	4.55e-05	0.000797	CcSEcCtD
Mesalazine—Urinary tract disorder—Methotrexate—psoriatic arthritis	4.52e-05	0.000793	CcSEcCtD
Mesalazine—Vision blurred—Prednisone—psoriatic arthritis	4.5e-05	0.000789	CcSEcCtD
Mesalazine—Urethral disorder—Methotrexate—psoriatic arthritis	4.49e-05	0.000787	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	4.49e-05	0.000787	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	4.48e-05	0.000786	CcSEcCtD
Mesalazine—Anaphylactic shock—Dexamethasone—psoriatic arthritis	4.47e-05	0.000784	CcSEcCtD
Mesalazine—Anaphylactic shock—Betamethasone—psoriatic arthritis	4.47e-05	0.000784	CcSEcCtD
Mesalazine—Oedema—Dexamethasone—psoriatic arthritis	4.47e-05	0.000784	CcSEcCtD
Mesalazine—Oedema—Betamethasone—psoriatic arthritis	4.47e-05	0.000784	CcSEcCtD
Mesalazine—Insomnia—Triamcinolone—psoriatic arthritis	4.46e-05	0.000782	CcSEcCtD
Mesalazine—Insomnia—Methylprednisolone—psoriatic arthritis	4.45e-05	0.00078	CcSEcCtD
Mesalazine—Infection—Dexamethasone—psoriatic arthritis	4.44e-05	0.000779	CcSEcCtD
Mesalazine—Infection—Betamethasone—psoriatic arthritis	4.44e-05	0.000779	CcSEcCtD
Mesalazine—Ill-defined disorder—Prednisone—psoriatic arthritis	4.43e-05	0.000776	CcSEcCtD
Mesalazine—Paraesthesia—Triamcinolone—psoriatic arthritis	4.42e-05	0.000776	CcSEcCtD
Mesalazine—Feeling abnormal—Prednisolone—psoriatic arthritis	4.42e-05	0.000774	CcSEcCtD
Mesalazine—Paraesthesia—Methylprednisolone—psoriatic arthritis	4.41e-05	0.000774	CcSEcCtD
Mesalazine—Anaemia—Prednisone—psoriatic arthritis	4.41e-05	0.000773	CcSEcCtD
Mesalazine—Shock—Betamethasone—psoriatic arthritis	4.4e-05	0.000771	CcSEcCtD
Mesalazine—Shock—Dexamethasone—psoriatic arthritis	4.4e-05	0.000771	CcSEcCtD
Mesalazine—Dyspnoea—Triamcinolone—psoriatic arthritis	4.39e-05	0.00077	CcSEcCtD
Mesalazine—Nervous system disorder—Betamethasone—psoriatic arthritis	4.38e-05	0.000769	CcSEcCtD
Mesalazine—Nervous system disorder—Dexamethasone—psoriatic arthritis	4.38e-05	0.000769	CcSEcCtD
Mesalazine—Thrombocytopenia—Betamethasone—psoriatic arthritis	4.38e-05	0.000768	CcSEcCtD
Mesalazine—Thrombocytopenia—Dexamethasone—psoriatic arthritis	4.38e-05	0.000768	CcSEcCtD
Mesalazine—Tachycardia—Betamethasone—psoriatic arthritis	4.36e-05	0.000765	CcSEcCtD
Mesalazine—Tachycardia—Dexamethasone—psoriatic arthritis	4.36e-05	0.000765	CcSEcCtD
Mesalazine—Angioedema—Prednisone—psoriatic arthritis	4.36e-05	0.000765	CcSEcCtD
Mesalazine—Dyspepsia—Triamcinolone—psoriatic arthritis	4.34e-05	0.000761	CcSEcCtD
Mesalazine—Erythema multiforme—Methotrexate—psoriatic arthritis	4.33e-05	0.000759	CcSEcCtD
Mesalazine—Dyspepsia—Methylprednisolone—psoriatic arthritis	4.33e-05	0.000759	CcSEcCtD
Mesalazine—Hyperhidrosis—Betamethasone—psoriatic arthritis	4.32e-05	0.000758	CcSEcCtD
Mesalazine—Hyperhidrosis—Dexamethasone—psoriatic arthritis	4.32e-05	0.000758	CcSEcCtD
Mesalazine—Malaise—Prednisone—psoriatic arthritis	4.3e-05	0.000755	CcSEcCtD
Mesalazine—Vertigo—Prednisone—psoriatic arthritis	4.29e-05	0.000752	CcSEcCtD
Mesalazine—Eye disorder—Methotrexate—psoriatic arthritis	4.28e-05	0.000751	CcSEcCtD
Mesalazine—Syncope—Prednisone—psoriatic arthritis	4.28e-05	0.00075	CcSEcCtD
Mesalazine—Tinnitus—Methotrexate—psoriatic arthritis	4.27e-05	0.000749	CcSEcCtD
Mesalazine—Anorexia—Dexamethasone—psoriatic arthritis	4.26e-05	0.000747	CcSEcCtD
Mesalazine—Anorexia—Betamethasone—psoriatic arthritis	4.26e-05	0.000747	CcSEcCtD
Mesalazine—Urticaria—Prednisolone—psoriatic arthritis	4.26e-05	0.000747	CcSEcCtD
Mesalazine—Cardiac disorder—Methotrexate—psoriatic arthritis	4.25e-05	0.000745	CcSEcCtD
Mesalazine—Fatigue—Triamcinolone—psoriatic arthritis	4.25e-05	0.000745	CcSEcCtD
Mesalazine—Fatigue—Methylprednisolone—psoriatic arthritis	4.24e-05	0.000743	CcSEcCtD
Mesalazine—Pain—Triamcinolone—psoriatic arthritis	4.21e-05	0.000739	CcSEcCtD
Mesalazine—Loss of consciousness—Prednisone—psoriatic arthritis	4.19e-05	0.000735	CcSEcCtD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	4.18e-05	0.000972	CbGpPWpGaD
Mesalazine—Hypotension—Betamethasone—psoriatic arthritis	4.18e-05	0.000733	CcSEcCtD
Mesalazine—Hypotension—Dexamethasone—psoriatic arthritis	4.18e-05	0.000733	CcSEcCtD
Mesalazine—IKBKB—Innate Immune System—NOD2—psoriatic arthritis	4.17e-05	0.000968	CbGpPWpGaD
Mesalazine—Angiopathy—Methotrexate—psoriatic arthritis	4.16e-05	0.000729	CcSEcCtD
Mesalazine—Immune system disorder—Methotrexate—psoriatic arthritis	4.14e-05	0.000726	CcSEcCtD
Mesalazine—Mediastinal disorder—Methotrexate—psoriatic arthritis	4.13e-05	0.000724	CcSEcCtD
Mesalazine—Hypertension—Prednisone—psoriatic arthritis	4.12e-05	0.000722	CcSEcCtD
Mesalazine—Chills—Methotrexate—psoriatic arthritis	4.11e-05	0.000721	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	4.07e-05	0.000714	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	4.07e-05	0.000714	CcSEcCtD
Mesalazine—Arthralgia—Prednisone—psoriatic arthritis	4.06e-05	0.000712	CcSEcCtD
Mesalazine—Myalgia—Prednisone—psoriatic arthritis	4.06e-05	0.000712	CcSEcCtD
Mesalazine—Feeling abnormal—Triamcinolone—psoriatic arthritis	4.06e-05	0.000712	CcSEcCtD
Mesalazine—Feeling abnormal—Methylprednisolone—psoriatic arthritis	4.05e-05	0.000711	CcSEcCtD
Mesalazine—Anxiety—Prednisone—psoriatic arthritis	4.05e-05	0.00071	CcSEcCtD
Mesalazine—Alopecia—Methotrexate—psoriatic arthritis	4.05e-05	0.00071	CcSEcCtD
Mesalazine—Insomnia—Betamethasone—psoriatic arthritis	4.04e-05	0.000709	CcSEcCtD
Mesalazine—Insomnia—Dexamethasone—psoriatic arthritis	4.04e-05	0.000709	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	4.03e-05	0.000707	CcSEcCtD
Mesalazine—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	4.02e-05	0.000705	CcSEcCtD
Mesalazine—Paraesthesia—Betamethasone—psoriatic arthritis	4.01e-05	0.000704	CcSEcCtD
Mesalazine—Paraesthesia—Dexamethasone—psoriatic arthritis	4.01e-05	0.000704	CcSEcCtD
Mesalazine—Discomfort—Prednisone—psoriatic arthritis	4.01e-05	0.000704	CcSEcCtD
Mesalazine—Mental disorder—Methotrexate—psoriatic arthritis	4.01e-05	0.000704	CcSEcCtD
Mesalazine—Erythema—Methotrexate—psoriatic arthritis	3.99e-05	0.000699	CcSEcCtD
Mesalazine—CHUK—Immune System—REL—psoriatic arthritis	3.95e-05	0.000918	CbGpPWpGaD
Mesalazine—Hypersensitivity—Prednisolone—psoriatic arthritis	3.95e-05	0.000692	CcSEcCtD
Mesalazine—PTGS2—Selenium Micronutrient Network—TNF—psoriatic arthritis	3.94e-05	0.000915	CbGpPWpGaD
Mesalazine—Dyspepsia—Dexamethasone—psoriatic arthritis	3.94e-05	0.00069	CcSEcCtD
Mesalazine—Dyspepsia—Betamethasone—psoriatic arthritis	3.94e-05	0.00069	CcSEcCtD
Mesalazine—Urticaria—Triamcinolone—psoriatic arthritis	3.91e-05	0.000687	CcSEcCtD
Mesalazine—Urticaria—Methylprednisolone—psoriatic arthritis	3.91e-05	0.000685	CcSEcCtD
Mesalazine—Dysgeusia—Methotrexate—psoriatic arthritis	3.9e-05	0.000685	CcSEcCtD
Mesalazine—Body temperature increased—Triamcinolone—psoriatic arthritis	3.9e-05	0.000683	CcSEcCtD
Mesalazine—Anaphylactic shock—Prednisone—psoriatic arthritis	3.89e-05	0.000683	CcSEcCtD
Mesalazine—Oedema—Prednisone—psoriatic arthritis	3.89e-05	0.000683	CcSEcCtD
Mesalazine—Abdominal pain—Methylprednisolone—psoriatic arthritis	3.89e-05	0.000682	CcSEcCtD
Mesalazine—Decreased appetite—Betamethasone—psoriatic arthritis	3.89e-05	0.000682	CcSEcCtD
Mesalazine—Decreased appetite—Dexamethasone—psoriatic arthritis	3.89e-05	0.000682	CcSEcCtD
Mesalazine—Infection—Prednisone—psoriatic arthritis	3.87e-05	0.000678	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	3.86e-05	0.000677	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	3.86e-05	0.000677	CcSEcCtD
Mesalazine—Back pain—Methotrexate—psoriatic arthritis	3.86e-05	0.000676	CcSEcCtD
Mesalazine—Fatigue—Dexamethasone—psoriatic arthritis	3.85e-05	0.000676	CcSEcCtD
Mesalazine—Fatigue—Betamethasone—psoriatic arthritis	3.85e-05	0.000676	CcSEcCtD
Mesalazine—Shock—Prednisone—psoriatic arthritis	3.83e-05	0.000672	CcSEcCtD
Mesalazine—Pain—Dexamethasone—psoriatic arthritis	3.82e-05	0.000671	CcSEcCtD
Mesalazine—Pain—Betamethasone—psoriatic arthritis	3.82e-05	0.000671	CcSEcCtD
Mesalazine—Nervous system disorder—Prednisone—psoriatic arthritis	3.82e-05	0.00067	CcSEcCtD
Mesalazine—Tachycardia—Prednisone—psoriatic arthritis	3.8e-05	0.000666	CcSEcCtD
Mesalazine—Skin disorder—Prednisone—psoriatic arthritis	3.78e-05	0.000663	CcSEcCtD
Mesalazine—Hyperhidrosis—Prednisone—psoriatic arthritis	3.76e-05	0.00066	CcSEcCtD
Mesalazine—Vision blurred—Methotrexate—psoriatic arthritis	3.76e-05	0.000659	CcSEcCtD
Mesalazine—Anorexia—Prednisone—psoriatic arthritis	3.71e-05	0.000651	CcSEcCtD
Mesalazine—Ill-defined disorder—Methotrexate—psoriatic arthritis	3.7e-05	0.000649	CcSEcCtD
Mesalazine—CHUK—Innate Immune System—HLA-B—psoriatic arthritis	3.69e-05	0.000858	CbGpPWpGaD
Mesalazine—Anaemia—Methotrexate—psoriatic arthritis	3.68e-05	0.000646	CcSEcCtD
Mesalazine—Feeling abnormal—Dexamethasone—psoriatic arthritis	3.68e-05	0.000646	CcSEcCtD
Mesalazine—Feeling abnormal—Betamethasone—psoriatic arthritis	3.68e-05	0.000646	CcSEcCtD
Mesalazine—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	3.66e-05	0.000641	CcSEcCtD
Mesalazine—Gastrointestinal pain—Betamethasone—psoriatic arthritis	3.66e-05	0.000641	CcSEcCtD
Mesalazine—CHUK—Immune System—HLA-C—psoriatic arthritis	3.64e-05	0.000845	CbGpPWpGaD
Mesalazine—Hypersensitivity—Triamcinolone—psoriatic arthritis	3.63e-05	0.000637	CcSEcCtD
Mesalazine—Hypersensitivity—Methylprednisolone—psoriatic arthritis	3.62e-05	0.000635	CcSEcCtD
Mesalazine—IKBKB—MAPK Signaling Pathway—TNF—psoriatic arthritis	3.6e-05	0.000835	CbGpPWpGaD
Mesalazine—Malaise—Methotrexate—psoriatic arthritis	3.6e-05	0.000631	CcSEcCtD
Mesalazine—IKBKB—Immune System—REL—psoriatic arthritis	3.58e-05	0.000833	CbGpPWpGaD
Mesalazine—Vertigo—Methotrexate—psoriatic arthritis	3.58e-05	0.000628	CcSEcCtD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	3.58e-05	0.000831	CbGpPWpGaD
Mesalazine—Leukopenia—Methotrexate—psoriatic arthritis	3.57e-05	0.000626	CcSEcCtD
Mesalazine—Urticaria—Betamethasone—psoriatic arthritis	3.55e-05	0.000623	CcSEcCtD
Mesalazine—Urticaria—Dexamethasone—psoriatic arthritis	3.55e-05	0.000623	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	3.55e-05	0.000622	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—HLA-B—psoriatic arthritis	3.55e-05	0.000824	CbGpPWpGaD
Mesalazine—Dizziness—Prednisolone—psoriatic arthritis	3.54e-05	0.000621	CcSEcCtD
Mesalazine—Asthenia—Triamcinolone—psoriatic arthritis	3.54e-05	0.00062	CcSEcCtD
Mesalazine—Abdominal pain—Dexamethasone—psoriatic arthritis	3.53e-05	0.00062	CcSEcCtD
Mesalazine—Abdominal pain—Betamethasone—psoriatic arthritis	3.53e-05	0.00062	CcSEcCtD
Mesalazine—Body temperature increased—Betamethasone—psoriatic arthritis	3.53e-05	0.00062	CcSEcCtD
Mesalazine—Body temperature increased—Dexamethasone—psoriatic arthritis	3.53e-05	0.00062	CcSEcCtD
Mesalazine—Asthenia—Methylprednisolone—psoriatic arthritis	3.53e-05	0.000619	CcSEcCtD
Mesalazine—Insomnia—Prednisone—psoriatic arthritis	3.52e-05	0.000618	CcSEcCtD
Mesalazine—Paraesthesia—Prednisone—psoriatic arthritis	3.5e-05	0.000613	CcSEcCtD
Mesalazine—Pruritus—Triamcinolone—psoriatic arthritis	3.49e-05	0.000611	CcSEcCtD
Mesalazine—Cough—Methotrexate—psoriatic arthritis	3.48e-05	0.00061	CcSEcCtD
Mesalazine—Pruritus—Methylprednisolone—psoriatic arthritis	3.48e-05	0.00061	CcSEcCtD
Mesalazine—Dyspepsia—Prednisone—psoriatic arthritis	3.43e-05	0.000601	CcSEcCtD
Mesalazine—PTGS1—skin of body—psoriatic arthritis	3.42e-05	0.0337	CbGeAlD
Mesalazine—Arthralgia—Methotrexate—psoriatic arthritis	3.39e-05	0.000595	CcSEcCtD
Mesalazine—Chest pain—Methotrexate—psoriatic arthritis	3.39e-05	0.000595	CcSEcCtD
Mesalazine—Myalgia—Methotrexate—psoriatic arthritis	3.39e-05	0.000595	CcSEcCtD
Mesalazine—Decreased appetite—Prednisone—psoriatic arthritis	3.38e-05	0.000594	CcSEcCtD
Mesalazine—Rash—Prednisolone—psoriatic arthritis	3.38e-05	0.000593	CcSEcCtD
Mesalazine—Dermatitis—Prednisolone—psoriatic arthritis	3.38e-05	0.000592	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	3.37e-05	0.000591	CcSEcCtD
Mesalazine—Diarrhoea—Methylprednisolone—psoriatic arthritis	3.36e-05	0.00059	CcSEcCtD
Mesalazine—Fatigue—Prednisone—psoriatic arthritis	3.36e-05	0.000589	CcSEcCtD
Mesalazine—Headache—Prednisolone—psoriatic arthritis	3.36e-05	0.000589	CcSEcCtD
Mesalazine—Discomfort—Methotrexate—psoriatic arthritis	3.35e-05	0.000588	CcSEcCtD
Mesalazine—IKBKB—Innate Immune System—HLA-B—psoriatic arthritis	3.35e-05	0.000778	CbGpPWpGaD
Mesalazine—Constipation—Prednisone—psoriatic arthritis	3.33e-05	0.000584	CcSEcCtD
Mesalazine—IKBKB—Immune System—HLA-C—psoriatic arthritis	3.3e-05	0.000766	CbGpPWpGaD
Mesalazine—Confusional state—Methotrexate—psoriatic arthritis	3.28e-05	0.000575	CcSEcCtD
Mesalazine—PTGS2—skin of body—psoriatic arthritis	3.27e-05	0.0322	CbGeAlD
Mesalazine—CHUK—Innate Immune System—CRP—psoriatic arthritis	3.26e-05	0.000758	CbGpPWpGaD
Mesalazine—Dizziness—Triamcinolone—psoriatic arthritis	3.26e-05	0.000571	CcSEcCtD
Mesalazine—Anaphylactic shock—Methotrexate—psoriatic arthritis	3.25e-05	0.000571	CcSEcCtD
Mesalazine—Dizziness—Methylprednisolone—psoriatic arthritis	3.25e-05	0.00057	CcSEcCtD
Mesalazine—Infection—Methotrexate—psoriatic arthritis	3.23e-05	0.000567	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—HLA-B—psoriatic arthritis	3.22e-05	0.000747	CbGpPWpGaD
Mesalazine—Feeling abnormal—Prednisone—psoriatic arthritis	3.21e-05	0.000563	CcSEcCtD
Mesalazine—Asthenia—Betamethasone—psoriatic arthritis	3.21e-05	0.000563	CcSEcCtD
Mesalazine—Asthenia—Dexamethasone—psoriatic arthritis	3.21e-05	0.000563	CcSEcCtD
Mesalazine—Nervous system disorder—Methotrexate—psoriatic arthritis	3.19e-05	0.00056	CcSEcCtD
Mesalazine—Thrombocytopenia—Methotrexate—psoriatic arthritis	3.19e-05	0.000559	CcSEcCtD
Mesalazine—Gastrointestinal pain—Prednisone—psoriatic arthritis	3.18e-05	0.000558	CcSEcCtD
Mesalazine—Nausea—Prednisolone—psoriatic arthritis	3.18e-05	0.000558	CcSEcCtD
Mesalazine—Pruritus—Betamethasone—psoriatic arthritis	3.16e-05	0.000555	CcSEcCtD
Mesalazine—Pruritus—Dexamethasone—psoriatic arthritis	3.16e-05	0.000555	CcSEcCtD
Mesalazine—Skin disorder—Methotrexate—psoriatic arthritis	3.16e-05	0.000554	CcSEcCtD
Mesalazine—Hyperhidrosis—Methotrexate—psoriatic arthritis	3.15e-05	0.000552	CcSEcCtD
Mesalazine—Vomiting—Triamcinolone—psoriatic arthritis	3.13e-05	0.000549	CcSEcCtD
Mesalazine—Vomiting—Methylprednisolone—psoriatic arthritis	3.13e-05	0.000548	CcSEcCtD
Mesalazine—PTGS2—Spinal Cord Injury—TNF—psoriatic arthritis	3.12e-05	0.000724	CbGpPWpGaD
Mesalazine—Rash—Triamcinolone—psoriatic arthritis	3.11e-05	0.000545	CcSEcCtD
Mesalazine—Dermatitis—Triamcinolone—psoriatic arthritis	3.1e-05	0.000544	CcSEcCtD
Mesalazine—Anorexia—Methotrexate—psoriatic arthritis	3.1e-05	0.000544	CcSEcCtD
Mesalazine—Rash—Methylprednisolone—psoriatic arthritis	3.1e-05	0.000544	CcSEcCtD
Mesalazine—Dermatitis—Methylprednisolone—psoriatic arthritis	3.1e-05	0.000543	CcSEcCtD
Mesalazine—Urticaria—Prednisone—psoriatic arthritis	3.09e-05	0.000542	CcSEcCtD
Mesalazine—Headache—Triamcinolone—psoriatic arthritis	3.09e-05	0.000541	CcSEcCtD
Mesalazine—Headache—Methylprednisolone—psoriatic arthritis	3.08e-05	0.00054	CcSEcCtD
Mesalazine—Abdominal pain—Prednisone—psoriatic arthritis	3.08e-05	0.00054	CcSEcCtD
Mesalazine—Body temperature increased—Prednisone—psoriatic arthritis	3.08e-05	0.00054	CcSEcCtD
Mesalazine—Diarrhoea—Betamethasone—psoriatic arthritis	3.06e-05	0.000536	CcSEcCtD
Mesalazine—Diarrhoea—Dexamethasone—psoriatic arthritis	3.06e-05	0.000536	CcSEcCtD
Mesalazine—Hypotension—Methotrexate—psoriatic arthritis	3.04e-05	0.000533	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	3e-05	0.000697	CbGpPWpGaD
Mesalazine—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	2.96e-05	0.00052	CcSEcCtD
Mesalazine—IKBKB—Innate Immune System—CRP—psoriatic arthritis	2.96e-05	0.000688	CbGpPWpGaD
Mesalazine—Dizziness—Dexamethasone—psoriatic arthritis	2.96e-05	0.000519	CcSEcCtD
Mesalazine—Dizziness—Betamethasone—psoriatic arthritis	2.96e-05	0.000519	CcSEcCtD
Mesalazine—Insomnia—Methotrexate—psoriatic arthritis	2.94e-05	0.000516	CcSEcCtD
Mesalazine—Nausea—Triamcinolone—psoriatic arthritis	2.93e-05	0.000513	CcSEcCtD
Mesalazine—Paraesthesia—Methotrexate—psoriatic arthritis	2.92e-05	0.000512	CcSEcCtD
Mesalazine—Nausea—Methylprednisolone—psoriatic arthritis	2.92e-05	0.000512	CcSEcCtD
Mesalazine—Dyspnoea—Methotrexate—psoriatic arthritis	2.9e-05	0.000509	CcSEcCtD
Mesalazine—Somnolence—Methotrexate—psoriatic arthritis	2.89e-05	0.000507	CcSEcCtD
Mesalazine—Hypersensitivity—Prednisone—psoriatic arthritis	2.87e-05	0.000503	CcSEcCtD
Mesalazine—Dyspepsia—Methotrexate—psoriatic arthritis	2.86e-05	0.000502	CcSEcCtD
Mesalazine—Vomiting—Dexamethasone—psoriatic arthritis	2.84e-05	0.000499	CcSEcCtD
Mesalazine—Vomiting—Betamethasone—psoriatic arthritis	2.84e-05	0.000499	CcSEcCtD
Mesalazine—Decreased appetite—Methotrexate—psoriatic arthritis	2.83e-05	0.000496	CcSEcCtD
Mesalazine—Rash—Betamethasone—psoriatic arthritis	2.82e-05	0.000494	CcSEcCtD
Mesalazine—Rash—Dexamethasone—psoriatic arthritis	2.82e-05	0.000494	CcSEcCtD
Mesalazine—Dermatitis—Betamethasone—psoriatic arthritis	2.82e-05	0.000494	CcSEcCtD
Mesalazine—Dermatitis—Dexamethasone—psoriatic arthritis	2.82e-05	0.000494	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	2.81e-05	0.000493	CcSEcCtD
Mesalazine—Fatigue—Methotrexate—psoriatic arthritis	2.81e-05	0.000492	CcSEcCtD
Mesalazine—Headache—Dexamethasone—psoriatic arthritis	2.8e-05	0.000491	CcSEcCtD
Mesalazine—Headache—Betamethasone—psoriatic arthritis	2.8e-05	0.000491	CcSEcCtD
Mesalazine—Asthenia—Prednisone—psoriatic arthritis	2.79e-05	0.00049	CcSEcCtD
Mesalazine—Pain—Methotrexate—psoriatic arthritis	2.78e-05	0.000488	CcSEcCtD
Mesalazine—Pruritus—Prednisone—psoriatic arthritis	2.75e-05	0.000483	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	2.72e-05	0.000632	CbGpPWpGaD
Mesalazine—Feeling abnormal—Methotrexate—psoriatic arthritis	2.68e-05	0.00047	CcSEcCtD
Mesalazine—CHUK—Immune System—NOD2—psoriatic arthritis	2.68e-05	0.000622	CbGpPWpGaD
Mesalazine—Diarrhoea—Prednisone—psoriatic arthritis	2.66e-05	0.000467	CcSEcCtD
Mesalazine—Gastrointestinal pain—Methotrexate—psoriatic arthritis	2.66e-05	0.000467	CcSEcCtD
Mesalazine—Nausea—Betamethasone—psoriatic arthritis	2.66e-05	0.000466	CcSEcCtD
Mesalazine—Nausea—Dexamethasone—psoriatic arthritis	2.66e-05	0.000466	CcSEcCtD
Mesalazine—PTGS1—tendon—psoriatic arthritis	2.6e-05	0.0256	CbGeAlD
Mesalazine—Urticaria—Methotrexate—psoriatic arthritis	2.58e-05	0.000453	CcSEcCtD
Mesalazine—Dizziness—Prednisone—psoriatic arthritis	2.57e-05	0.000452	CcSEcCtD
Mesalazine—Body temperature increased—Methotrexate—psoriatic arthritis	2.57e-05	0.000451	CcSEcCtD
Mesalazine—Abdominal pain—Methotrexate—psoriatic arthritis	2.57e-05	0.000451	CcSEcCtD
Mesalazine—PTGS2—tendon—psoriatic arthritis	2.49e-05	0.0245	CbGeAlD
Mesalazine—Vomiting—Prednisone—psoriatic arthritis	2.48e-05	0.000434	CcSEcCtD
Mesalazine—Rash—Prednisone—psoriatic arthritis	2.45e-05	0.000431	CcSEcCtD
Mesalazine—Dermatitis—Prednisone—psoriatic arthritis	2.45e-05	0.00043	CcSEcCtD
Mesalazine—Headache—Prednisone—psoriatic arthritis	2.44e-05	0.000428	CcSEcCtD
Mesalazine—IKBKB—Immune System—NOD2—psoriatic arthritis	2.43e-05	0.000564	CbGpPWpGaD
Mesalazine—Hypersensitivity—Methotrexate—psoriatic arthritis	2.4e-05	0.00042	CcSEcCtD
Mesalazine—Asthenia—Methotrexate—psoriatic arthritis	2.33e-05	0.000409	CcSEcCtD
Mesalazine—Nausea—Prednisone—psoriatic arthritis	2.31e-05	0.000406	CcSEcCtD
Mesalazine—Pruritus—Methotrexate—psoriatic arthritis	2.3e-05	0.000404	CcSEcCtD
Mesalazine—Diarrhoea—Methotrexate—psoriatic arthritis	2.23e-05	0.00039	CcSEcCtD
Mesalazine—Dizziness—Methotrexate—psoriatic arthritis	2.15e-05	0.000377	CcSEcCtD
Mesalazine—CHUK—Immune System—HLA-B—psoriatic arthritis	2.15e-05	0.0005	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	2.12e-05	0.000493	CbGpPWpGaD
Mesalazine—Vomiting—Methotrexate—psoriatic arthritis	2.07e-05	0.000363	CcSEcCtD
Mesalazine—Rash—Methotrexate—psoriatic arthritis	2.05e-05	0.00036	CcSEcCtD
Mesalazine—Dermatitis—Methotrexate—psoriatic arthritis	2.05e-05	0.000359	CcSEcCtD
Mesalazine—Headache—Methotrexate—psoriatic arthritis	2.04e-05	0.000358	CcSEcCtD
Mesalazine—IKBKB—Immune System—HLA-B—psoriatic arthritis	1.95e-05	0.000453	CbGpPWpGaD
Mesalazine—Nausea—Methotrexate—psoriatic arthritis	1.93e-05	0.000339	CcSEcCtD
Mesalazine—CHUK—Immune System—CRP—psoriatic arthritis	1.9e-05	0.000442	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HLA-DRB1—psoriatic arthritis	1.82e-05	0.000423	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—TNF—psoriatic arthritis	1.78e-05	0.000414	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CRP—psoriatic arthritis	1.72e-05	0.000401	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HLA-DRB1—psoriatic arthritis	1.65e-05	0.000384	CbGpPWpGaD
Mesalazine—CHUK—Disease—NOS2—psoriatic arthritis	1.6e-05	0.000372	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOS2—psoriatic arthritis	9.48e-06	0.00022	CbGpPWpGaD
